TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00970320

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor muscle training
Description: 6 months of daily pelvic floor exercise treatment with regular follow up by specialist physiotherapist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor muscle training
Description: 6 months of daily pelvic floor exercise treatment with regular follow up by specialist physiotherapist.
Study: NCT04460729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capmatinib
Description: 400 mg administered orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capmatinib
Description: 400 mg administered orally twice daily
Study: NCT03587779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Throughout the study period, anesthesia is maintained with sevoflurane of age-corrected equivalent minimum alveolar concentration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: Throughout the study period, anesthesia is maintained with desflurane of age-corrected equivalent minimum alveolar concentration.
Study: NCT04212780

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic Summit Rechargable (RC)+S
Description: Dual channel closed-loop pulse generator with connection to both new DBS leads for deep stimulation of VIM vs VO

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic Summit Rechargable (RC)+S
Description: Dual channel closed-loop pulse generator with connection to both new DBS leads for deep stimulation of VIM vs VO

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ipsilateral thalamic (VIM+VO) DBS
Description: Implantation of two new ipsilateral thalamic (VIM+VO) DBS

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard ET DBS
Description: Single Lead VIM

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ipsilateral VO
Description: second lead in the ipsilateral VO
Study: NCT03089736

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Six education areas was offered: pain and pain physiology, pain medication, side effects and prevention of side effects, abuse of medications, sleep advice and advice on anxiety.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self Care
Description: The following instructions on self-care for pain relief: apply ice or crushed ice in the oral cavity, lubricating and antiseptic mouth rinses, pain relieving gel, tongue movements and gaps exercises. Prevention of dryness in the mouth and throat; saliva stimulants and saliva substitute agents in different preparations, increased measures of good oral hygiene. Physical activities and regular rest once to several times per day. Sleep restriction and measures to treat sleep disorders.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual (TAU)
Description: pharmacological treatment + advices

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual (TAU)
Description: pharmacological treatment + advices
Study: NCT00936962

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeisVac C vaccine (12mth)
Description: NeisVac C Meningococcal C Conjugate vaccine given IM 0.5mL in the deltoid muscle at 12 mths of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeisVac C vaccine (12mth)
Description: NeisVac C Meningococcal C Conjugate vaccine given IM 0.5mL in the deltoid muscle at 12 mths of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeisVac C vaccine (12mth)
Description: NeisVac C Meningococcal C Conjugate vaccine given IM 0.5mL in the deltoid muscle at 12 mths of age
Study: NCT00077597

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epoetin
Description: 3 times a week iv, as prescribed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: 0.4 micrograms/kg iv (starting dose) once every 2 weeks
Study: NCT00345709

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: 65 page questionnaire that contains questions about your ovarian cancer diagnosis, gynecologic history, family history, general medical history, and health risk factors.
Study: NCT04634955

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tranforaminal epidural injection
Description: tranforaminal epidural injection which is performed by fluoroscopic guidance

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tranforaminal epidural injection
Description: tranforaminal epidural injection which is performed by fluoroscopic guidance
Study: NCT05000099

Intervention type: OTHER
Intervention: video calls
Description: A tablet for video-calls will be available for patients and families. Two video-calls of maximum 15' will be organized every week; in addition, patients will be allowed to do video-call upon request. Video-calls will be performed using Skype or WhatsApp video or Face-time

Intervention type: OTHER
Intervention: video calls
Description: A tablet for video-calls will be available for patients and families. Two video-calls of maximum 15' will be organized every week; in addition, patients will be allowed to do video-call upon request. Video-calls will be performed using Skype or WhatsApp video or Face-time
Study: NCT02960945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-543, 16 mg (2 x 8 mg tablet)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Jakafi 15Mg Tablet
Study: NCT02743988

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Adapt inspired oxygen to achieve desired SpO2 target range

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: Adapt inspired oxygen to achieve desired SpO2 target range
Study: NCT02028247

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Cognitive-behavioral therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Practice Cognitive-behavioral therapy

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as Usual
Study: NCT03447275

Intervention type: OTHER
Intervention: Type 2 diabetes
Description: Test if patients with diabetes have different blood concentrations of vitamin biomarkers compared with control subjects and if vitamin levels in the patients will differ according to renal damage.

Intervention type: OTHER
Intervention: Type 2 diabetes
Description: Test if patients with diabetes have different blood concentrations of vitamin biomarkers compared with control subjects and if vitamin levels in the patients will differ according to renal damage.
Study: NCT03629899

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RETINA IMPLANT Alpha AMS
Description: Implantation of the subretinal RETINA IMPLANT Alpha AMS
Study: NCT02836041

Intervention type: BEHAVIORAL
Intervention: questionnaires
Description: Pre-hospital sleep questionnaire completed (Brief Infant Sleep Questionnaire (BISQ)7 in children 0-3 years old; Children's Sleep Habits Questionnaire (CSHQ)8 in children 4 years and older). Subsequent Day(s):~In-hospital sleep questionnaire completed between one and three times per subject (Sleep at MSK questionnaire (SAM), adapted from Sleep in a Children's Hospital (SinCH)9 by Dr. Lisa Meltzer). (Patients will be observed for up to 3 consecutive nights in total).

Intervention type: DEVICE
Intervention: actigraph
Description: This device reliably measures sleep by monitoring the child's motion.
Study: NCT03238807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Chorionic Gonadotropin
Description: 500 IU of human Chorionic Gonadotropin
Study: NCT03530436

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Native turmeric extract
Description: 207 mg curcumin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Native turmeric extract with 7-9% volatile turmeric oils
Description: 207 mg curcumin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Turmeric extract plus mixture of phytochemicals
Description: 207 mg curcumin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cyclodextrin complex of curcuminoids
Description: 207 mg curcumin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Turmeric oleoresin
Description: 207 mg curcumin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Liposomal curcumin
Description: 207 mg curcumin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Phytosomal curcumin
Description: 207 mg curcumin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micellar turmeric extract
Description: 207 mg curcumin
Study: NCT02525081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril (ACE-inhibitor)
Description: up to 10 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: up to 10 mg
Study: NCT01936324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olumacostat Glasaretil Gel, 7.5%
Description: Gel containing Olumacostat Glasaretil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olumacostat Glasaretil Gel, 7.5%
Description: Gel containing Olumacostat Glasaretil

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olumacostat Glasaretil Gel, Vehicle
Description: Vehicle (placebo) gel
Study: NCT03171532

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Strands of Hamstring Autograft in ACL reconstruction
Description: The femoral and tibial ends will be tubularised and the final graft diameter will be recorded after passing through sizing cylinders graduated in 0.5mm increments. The femoral and tibial tunnels will be drilled as per standard technique for single bundle ACL reconstruction via trans-portal or trans-tibial route and both ends fixed by interference screw with additional post on the tibial end.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Strands of Hamstring Autograft in ACL reconstruction
Description: The femoral and tibial ends will be tubularised and the final graft diameter will be recorded after passing through sizing cylinders graduated in 0.5mm increments. The femoral and tibial tunnels will be drilled as per standard technique for single bundle ACL reconstruction via trans-portal or trans-tibial route and both ends fixed by interference screw with additional post on the tibial end.
Study: NCT02344017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODM-204
Description: co-administered with prednisone, orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODM-204
Description: co-administered with prednisone, orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: ODM-204 is co-administered with oral prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: ODM-204 is co-administered with oral prednisone
Study: NCT00195884

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic and Resistance Exercise
Description: Aerobic activities are performed on a cycle ergometer or treadmill. Exercise intensity is standardized using Polar Heart rate monitors that display the subject's heart rate.~Resistance training:Exercises are performed at weight machines arranged in a circuit. Throughout the resistance training program, subjects will alternate between the exercises of group A and group B below.~Group A: abdominal crunches, seated row, seated biceps curls, supine bench press, leg press, shoulder press; leg extension Group B: abdominal crunches, lat pulldown, sitting chest press, leg press, upright row, triceps pushdown, leg curls.~Combined aerobic and resistance training group will perform both aerobic and resistance training programs, as described above.~Control: members of this group are asked to revert to their pre-study activity levels for 5 months, at which point they begin the combined aerobic and resistance exercise program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic and Resistance Exercise
Description: Aerobic activities are performed on a cycle ergometer or treadmill. Exercise intensity is standardized using Polar Heart rate monitors that display the subject's heart rate.~Resistance training:Exercises are performed at weight machines arranged in a circuit. Throughout the resistance training program, subjects will alternate between the exercises of group A and group B below.~Group A: abdominal crunches, seated row, seated biceps curls, supine bench press, leg press, shoulder press; leg extension Group B: abdominal crunches, lat pulldown, sitting chest press, leg press, upright row, triceps pushdown, leg curls.~Combined aerobic and resistance training group will perform both aerobic and resistance training programs, as described above.~Control: members of this group are asked to revert to their pre-study activity levels for 5 months, at which point they begin the combined aerobic and resistance exercise program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic and Resistance Exercise
Description: Aerobic activities are performed on a cycle ergometer or treadmill. Exercise intensity is standardized using Polar Heart rate monitors that display the subject's heart rate.~Resistance training:Exercises are performed at weight machines arranged in a circuit. Throughout the resistance training program, subjects will alternate between the exercises of group A and group B below.~Group A: abdominal crunches, seated row, seated biceps curls, supine bench press, leg press, shoulder press; leg extension Group B: abdominal crunches, lat pulldown, sitting chest press, leg press, upright row, triceps pushdown, leg curls.~Combined aerobic and resistance training group will perform both aerobic and resistance training programs, as described above.~Control: members of this group are asked to revert to their pre-study activity levels for 5 months, at which point they begin the combined aerobic and resistance exercise program.
Study: NCT03728959

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liquid meal (Nutridrink)
Description: Liquid meal ingested over 1 minute.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GIP
Description: Subcutaneous injected GIP

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GLP-2
Description: Subcutaneous injected GLP-2

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo (saline)
Description: Subcutaneous injected Placebo (saline)
Study: NCT04008056

Intervention type: OTHER
Intervention: Patient Reported Outcome questionnaire
Description: 34 question form to assess patient symptoms
Study: NCT00771095

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: podcasting

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: podcasting
Study: NCT03018223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Myeloablative conditioning: 40 mg/m\^2 daily for 4 days. Dose will be adjusted for estimated creatinine clearance. Reduced intensity conditioning: 30 mg/m\^2 daily on days -6, -5, -4, -3 and -2. Dose will be adjusted for estimated creatinine clearance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Myeloablative conditioning: IV dosing targeted for a daily total area under curve (AUC) 5300 mmol\*min/L for 4 days. Busulfan AUC will be pharmacokinetically targeted. An AUC 3500 mmol\*min/l may be considered in patients over 60 years of age or with multiple comorbidities. Chemotherapy may start on day -6 or day -5 depending on the day of admission (-6 for Wednesday admission, -5 for Sunday admission).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Reduced intensity conditioning: 14.5 mg/kg/day on days -6, -5. GVHD prophylaxis: 50 mg/kg ideal body weight (IBW) daily dose will be given on days +3 and +4 post-transplant as an IV infusion over 1-2 hours.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation (TBI)
Description: Reduced intensity conditioning: 200 centigray (cGy) on day -1.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Hematopoietic Cell Transplantation (HCT)
Description: On day 0, patients will receive a peripheral blood hematopoietic cell graft.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus (SIR)
Description: GVHD prophylaxis: SIR will be administered as a 9 mg oral loading dose on day +5, followed by maintenance. SIR levels will be monitored and maintenance dosing adjusted as needed for a target trough level 8 to 14 ng/ml, per Moffitt BMT program standard practice. In the absence of acute GVHD, sirolimus taper will start on day +90 (+/- 10 days) and it is suggested to finish by day +180.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Description: GVHD prophylaxis: MMF will start on day +5 at a dose of 15 mg/kg every 8 hours IV with the maximum daily dose not to exceed 3 gm. MMF will be changed to orally (PO) and discontinued on day +35 (without taper) in the absence of acute GVHD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte-colony stimulating factor (G-CSF)
Description: Growth factor support: G-CSF will be given beginning on day 5 at a dose of 5 mcg/kg/day (rounding to the nearest vial dose), until absolute granulocyte count (ANC) is \> 1,000/mm\^3 for three consecutive days. G-CSF may be given IV or subcutaneously.
Study: NCT00805597

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation
Description: radiotherapy of 50Gy/25f/5w to the chest wall and supraclavicular nodal region

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: no radiation
Description: no radiotherapy
Study: NCT01058525

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: median nerve block
Description: median nerve block performed using ultrasound guidance

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: median nerve block after hydro-dissection
Description: median nerve block performed after hydro-dissection (glucose 5% solution), both using ultrasound guidance
Study: NCT03801187

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: chlorhexidine
Description: Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in chlorhexidine.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: chlorhexidine
Description: Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in chlorhexidine.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: chlorhexidine
Description: Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in chlorhexidine.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Er:YAG laser
Description: Er.YAg laser treatment will be provided on the implant surface.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Air-Powder
Description: An air powder device will be treatment will be provided on the implant surface.
Study: NCT03507153

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bre-flex maxillary partial denture
Description: Partial denture fabricated from Bre.flex material.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEEK maxillary partial denture
Description: Partial denture fabricated from PEEK material.
Study: NCT02457442

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol and Remifentanil
Description: High propofol and low remifentanil, changing remifentanil (up-and-down method)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol and Remifentanil
Description: Low propofol and high remifentanil, changing propofol (up-and-down method)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane and Remifentanil
Description: High sevoflurane and low remifentanil, changing remifentanil (up-and-down method)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane and Remifentanil
Description: Low sevoflurane and high remifentanil, changing sevoflurane up-and-down method)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPR 1
Description: Triple combination with intermediate propofol and sevoflurane and intermediate remifentanil.~SPR 1: Changing Propofol for skin incision.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPR2
Description: Triple combination with intermediate propofol and sevoflurane and intermediate remifentanil.~Changing Sevoflurane for skin incision.
Study: NCT02803671

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TFU-NIRS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TFU-NIRS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TFU-NIRS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIRS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIRS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIRS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG
Study: NCT00477464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: 1250mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: 2000mg/m\^2 twice daily (14 days out of 21 days)
Study: NCT03532269

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nightly App
Description: The Nightly application will be installed independently on the user's smartphone. Once the user has set up their account and has logged in, they can then perform regular sleep quality assessments. In order to record a measurement, the user must first select a film (first screen) and watch it (second screen), the visualizations and acoustics aid in the process of falling asleep. After the film finishes, the participant places the phone on the corner of the bed, firstly with the screen facing up, and then under his/her pillow. Throughout the night, the application registers sleep phases that will be analyzed later.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nightly App
Description: The Nightly application will be installed independently on the user's smartphone. Once the user has set up their account and has logged in, they can then perform regular sleep quality assessments. In order to record a measurement, the user must first select a film (first screen) and watch it (second screen), the visualizations and acoustics aid in the process of falling asleep. After the film finishes, the participant places the phone on the corner of the bed, firstly with the screen facing up, and then under his/her pillow. Throughout the night, the application registers sleep phases that will be analyzed later.